275 related articles for article (PubMed ID: 27460005)
1. Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.
Yedinak CG; Cetas I; Ozpinar A; McCartney S; Dogan A; Fleseriu M
Endocrine; 2016 Oct; 54(1):191-197. PubMed ID: 27460005
[TBL] [Abstract][Full Text] [Related]
2. Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study.
Yedinak C; Hameed N; Gassner M; Brzana J; McCartney S; Fleseriu M
Pituitary; 2015 Oct; 18(5):701-9. PubMed ID: 25673267
[TBL] [Abstract][Full Text] [Related]
3. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
4. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
5. [Role of hypothalamo-hypophyseal-adrenal axis in the pathogenesis of arterial hypertension in patients with prolactinoma of the anterior lobe of the hypophysis].
Mychka VB; Chazova IE; Dmitriev VV; Masenko VP
Ter Arkh; 2000; 72(9):10-3. PubMed ID: 11076407
[TBL] [Abstract][Full Text] [Related]
6. Recovery of the Hypothalamo-Pituitary-Adrenal Axis After Transsphenoidal Adenomectomy for Non-ACTH-Secreting Macroadenomas.
Pofi R; Gunatilake S; Macgregor V; Shine B; Joseph R; Grossman AB; Isidori AM; Cudlip S; Jafar-Mohammadi B; Tomlinson JW; Pal A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5316-5324. PubMed ID: 31225871
[TBL] [Abstract][Full Text] [Related]
7. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma.
Zueger T; Kirchner P; Herren C; Fischli S; Zwahlen M; Christ E; Stettler C
J Clin Endocrinol Metab; 2012 Oct; 97(10):E1938-42. PubMed ID: 22872686
[TBL] [Abstract][Full Text] [Related]
9. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients.
Kreutzer J; Buslei R; Wallaschofski H; Hofmann B; Nimsky C; Fahlbusch R; Buchfelder M
Eur J Endocrinol; 2008 Jan; 158(1):11-8. PubMed ID: 18166812
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
11. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.
Bancos I; Nannenga MR; Bostwick JM; Silber MH; Erickson D; Nippoldt TB
Clin Endocrinol (Oxf); 2014 Jun; 80(6):863-8. PubMed ID: 24274365
[TBL] [Abstract][Full Text] [Related]
12. Peri-operative glucocorticoid replacement therapy in transsphenoidal pituitary adenoma surgery: a prospective controlled study.
Kristof RA; Wichers M; Haun D; Redel L; Klingmüller D; Schramm J
Acta Neurochir (Wien); 2008 Apr; 150(4):329-35; discussion 335. PubMed ID: 18309452
[TBL] [Abstract][Full Text] [Related]
13. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
14. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
15. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
17. The Role of Surgery in the Management of Prolactinomas.
Donoho DA; Laws ER
Neurosurg Clin N Am; 2019 Oct; 30(4):509-514. PubMed ID: 31471058
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
19. Dopamine agonists and pituitary tumor shrinkage.
Bevan JS; Webster J; Burke CW; Scanlon MF
Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
[TBL] [Abstract][Full Text] [Related]
20. Management of cystic prolactinomas: a review.
Nakhleh A; Shehadeh N; Hochberg I; Zloczower M; Zolotov S; Taher R; Daoud Naccache D
Pituitary; 2018 Aug; 21(4):425-430. PubMed ID: 29654440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
